Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q3 2026 Earnings Presentation
19 slides from Bactiguard Holding Ab's earnings presentation, Oct 22, 2026
Slide 1: Accelerating performance validates our partnership model
Accelerating performance validates our partnership model Q3 presentation Tuesday 22 October 2026 Christine Lind, CEO Patrick Bach, CFO
Slide 2: Accelerating performance validates our partnership model
Accelerating performance validates our partnership model Key figures for Q3 2026 (Q3 2025) Highlights Q3 • 24% net sales growth (excl. currency) Total revenue 58.4 (48.4) MSEK • License revenues up 40% (excl. currency), Adj. EBITDA 20.0 (5.3) MSEK mainly driven by strong BD revenue growth • 34% adju
Slide 3: BD partnership delivering strongest growth in a decade
BD partnership delivering strongest growth in a decade • Strongest BD revenue growth in a decade – 1 30% growth • Growing demand across both established and recently launched markets • Continued commercialization, technology training and market development activities in Europe • Increasing order vol
Slide 4: Zimmer Biomet – Bactiguard growing use in trauma patients
Zimmer Biomet – Bactiguard growing use in trauma patients • Growing contribution from market-based royalties – reflecting growing demand • Continued joint execution on regulatory programs and scientific publication and visibility strategy. Two conference presentations highlighting: ─ Durability of t
Slide 5: Meaningful headway across several initiatives – strongest engagement from partners within orthopedics
Meaningful headway across several initiatives – strongest engagement from partners within orthopedics Partnership snapshot Q3 2026 Material transfer Application development Exclusivity partnership License partnership agreement partnership Orthopedics Cardiology Neurology Urology Vascular access Othe
Slide 6: Hydrocyn aqua drives continued growth despite inherent quarterly variability
Hydrocyn aqua drives continued growth despite inherent quarterly variability • Double-digit organic growth for YTD 2026 (9 months) • Hydrocyn aqua continues to lead portfolio growth • Quarterly variability reflects product order phasing following a very strong Q2 • Continued investment in regulatory
Slide 7: Total revenue increased 21% excl. currency in Q3 driven by high growth from our license business
Total revenue increased 21% excl. currency in Q3 driven by high growth from our license business Total Revenue development constant currency MSEK Other revenues BIP portfolio Wound Management portfolio Total license revenue Third quarter (Jul-Sep) Year to date (Jan-Sep) Full year RTM 237,0 238,8 0,9
Slide 8: License revenues grew 40% in the quarter across partnerships, notably driven by BD
License revenues grew 40% in the quarter across partnerships, notably driven by BD License revenue development constant currency MSEK Application development partners Exclusivity partners License partners Third quarter (Jul-Sep) Year to date (Jan-Sep) Full year RTM 163,3 159,9 0,0 0,3 0,0 1,6 +0,7%
Slide 9: Continued flat total operating costs (OPEX) during the quarter and on YTD basis
Continued flat total operating costs (OPEX) during the quarter and on YTD basis Total operating costs (OPEX) development MSEK Personnel costs Other external expenses Other operating expenses Third quarter (Jul-Sep) Year to date (Jan-Sep) Full year RTM 153,7 154,3 0,4% 119,9 120,4 95,4 95,2 70,9 70,8
Slide 10: As a result, Adjusted EBITDA increased to SEK 20 million in Q3 and RTM increased to SEK 55 million
As a result, Adjusted EBITDA increased to SEK 20 million in Q3 and RTM increased to SEK 55 million Adjusted EBITDA development MSEK Adjusted EBITDA Third quarter (Jul-Sep) Year to date (Jan-Sep) Full year RTM 55.3 43.8 +11.5 30.6 +14.7 20.0 19.1 5.3 2025 2026 2025 2026 2025 2025/26 10
Slide 11: Strong cash flow from operations of SEK 14 million and solid cash position
Strong cash flow from operations of SEK 14 million and solid cash position at end of Q3 of SEK 55 million Cash flow for the period and total cash development MSEK 14,0 -0,2 -3,4 1,2 55,1 43,5 Cash end Cash flow Cash flow Cash flow Exchange Cash end of Q2 2026 from operating from investing from finan
Slide 12: Q3 profitability and cash flow highlight the execution and scalability of the business model
Q3 profitability and cash flow highlight the execution and scalability of the business model Adjusted EBITDA development MSEK Adjusted EBITDA (RTM) Total Cash Flow for the period (RTM) 55,3 27,5 14,3 5,3 -16,0 -20,3 -51.01 -74,8 -72,9 2023 2024 2025 2026 2023 2024 2025 2026 1 SEK 51 million voluntar
Slide 13: Resulting in lower net debt and reduced debt leverage
Resulting in lower net debt and reduced debt leverage Adjusted EBITDA development Net Debt incl. leasing liabilities Net Debt excl. leasing / Adjusted EBITDA SEK million Ratio 180.0 128.7 12.8x 111.5 45,7 98.7 60,5 Leasing 56,8 34,5 liabilities 3.0x Net debt 83,0 1.2x 68,4 64,2 excl 54,7 leasing -0,
Slide 14: Looking ahead: Building on our momentum
Looking ahead: Building on our momentum Strategic focus R&D Medical Wound Management License partnerships Regulatory portfolio Advance current and Continue to invest in Grow profitably and expand develop new partnerships key knowledge areas into new markets • Continued growth in the license business
Slide 15: Key takeaways
Key takeaways 24% net sales growth Strongest BD performance Market-based revenues from Driven by significant license in a decade Zimmer gaining momentum revenue growth of 40% Strong demand across both Growing contribution from (both constant currency) established and recently launched sales-based ro
Slide 16: Additional financial information
Additional financial information
Slide 17: Appendix – Reported revenue
Appendix – Reported revenue Reported Revenue development MSEK Other revenues BIP portfolio Wound Management portfolio Total license revenue Third quarter (Jul-Sep) Year to date (Jan-Sep) Full year RTM 228,8 227,9 0,9 12,8 0,0 13,2 -0,5% 163,2 162,4 62,7 67,5 0,9 10,4 0,0 10,8 48,7 53,4 20,8% 58,4 15
Slide 18: Appendix – Reported License revenue
Appendix – Reported License revenue Reported License revenue development MSEK Application development partners Exclusivity partners License partners Third quarter (Jul-Sep) Year to date (Jan-Sep) Full year RTM 152,3 147,3 0,0 0,3 0,0 1,5 -4,9% 103,2 98,2 0,0 0,1 0,0 1,3 37,5% 152,0 145,8 41,0 103,1
Slide 19: Appendix - EBITDA
Appendix - EBITDA EBITDA development MSEK EBITDA Third quarter (Jul-Sep) Year to date (Jan-Sep) Full year RTM 49.0 43.8 +5.2 +12.3 24.3 17.5 19.1 5.3 2025 2026 2025 2026 2025 2025/26 20